This is a registry record, not a result. A trial being listed, recruiting or completed says nothing by itself about whether the compound works or is safe.
| Registry number | NCT07890376 |
|---|---|
| Status | Not yet recruiting |
| Phase | Phase 2 |
| Sponsor | Eli Lilly and Company |
| Enrollment | 460 participants |
| Design | Interventional, Randomized, Parallel, Masking: Double |
| Conditions | Obesity; Overweight |
| Interventions | LY4086940; Placebo |
| Start | Nov 2026 |
| Primary completion | Jan 2028 |
| Study completion | Jun 2028 |
| Results posted | Not yet |
| Registry last updated | Oct 22, 2026 |
Compounds on this site that cite this trial
What the registry says the trial is about
The purpose of this study, performed under the master protocol W8M-MC- CWMM (NCT06143956), is to evaluate the efficacy and safety of LY4086940 compared with placebo in participants without type 2 diabetes who have obesity or who have overweight with a weight-related health condition.
Participation in the study will last about 58 weeks.
Primary outcomes
These are what the trial was designed to measure first. They are registered in advance, which is what makes a later result checkable.
| Outcome measure | Time frame |
|---|---|
| Percent Change from Baseline in Body Weight | Baseline, Week 32 |
4 secondary outcomes also registered. See the registry record for the full list.
Source: ClinicalTrials.gov (U.S. National Library of Medicine). Last checked against the registry on Oct 30, 2026. See the trial changes feed for what has changed recently.
More trials of LY4086940
More from Eli Lilly and Company
- Eloralintide and Tirzepatide: Phase 3 Trial (NCT07881432)
- A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, Type 2 Diabetes, and Increased (Phase 3 NCT07900633)
- Eloralintide and Tirzepatide: Phase 3 Trial (NCT07881458)
- RENEW-MDD 1: Brenipatide, Phase 3 (NCT07412756)
Research area: Metabolic and incretin. Every registered trial we follow is in the clinical trial tracker, and the labels used on this page are explained in our evidence standards.
